Letters Section Editor: Robert M. Golub,
MD, Senior Editor.
To the Editor: While the TADS trial provides
valuable data about a significant problem, we differ from the authors in their
conclusion that treatment with fluoxetine should be made widely available,
and that CBT in combination with fluoxetine should be “readily available
as part of comprehensive treatment for depressed adolescents.”1 Because 2 of 3 outcome measures (Clinical Global Impressions
[CGI] and Reynolds Adolescent Depression Scale [RADS]) show no significant
difference between fluoxetine treatment alone and fluoxetine in combination
with CBT, we do not see this study showing an advantage for the addition of
CBT in all adolescents with MDD.
Rifkin A, Rifkin W. Adolescents With Depression. JAMA. 2004;292(21):2577-2579. doi:10.1001/jama.292.21.2577-b